The influence of probiotic supplementation on gut permeability in patients with metabolic syndrome: An open label, randomized pilot study

European Journal of Clinical Nutrition

Volumn 66, Issue 10, 2012, Pages 1110-1115

  Leber, B ^a   Tripolt, N J ^a   Blattl, D ^a   Eder, M ^a   Wascher, T C ^b   Pieber, T R ^a   Stauber, R ^a   Sourij, H ^a   Oettl, K ^a   Stadlbauer, V ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b HANUSCH HOSPITAL   (Austria)

Author keywords

endotoxin; gut permeability; Lactobacillus casei Shirota; metabolic syndrome

Indexed keywords

AMINE OXIDASE (COPPER CONTAINING); C REACTIVE PROTEIN; CD14 ANTIGEN; ENDOTOXIN; LIPOPOLYSACCHARIDE BINDING PROTEIN; PROBIOTIC AGENT; TOLL LIKE RECEPTOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; INTESTINE MUCOSA PERMEABILITY; LACTOBACILLUS CASEI; LIMULUS LYSATE TEST; MALE; METABOLIC SYNDROME X; MICROFLORA; NEUTROPHIL; OXIDATIVE STRESS; PHAGOCYTOSIS; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY BURST;

ACUTE-PHASE PROTEINS; ADULT; AGED; AMINE OXIDASE (COPPER-CONTAINING); ANTIGENS, CD14; C-REACTIVE PROTEIN; CARRIER PROTEINS; COHORT STUDIES; ENDOTOXINS; FEMALE; HUMANS; INTESTINAL MUCOSA; LACTOBACILLUS CASEI; MALE; MEMBRANE GLYCOPROTEINS; METABOLIC SYNDROME X; MIDDLE AGED; NEUTROPHILS; PERMEABILITY; PILOT PROJECTS; PROBIOTICS; SOLUBILITY; YOUNG ADULT;

LACTOBACILLUS CASEI; LIMULUS AMOEBOCYTE;

EID: 84867096233     PISSN: 09543007     EISSN: 14765640     Source Type: Journal    
DOI: 10.1038/ejcn.2012.103     Document Type: Article

References (30)

1. Tilg H, Kaser A. Gut microbiome, obesity, and metabolic dysfunction. J Clin Invest 2011; 121: 2126-2132.
2. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest 2005; 115: 1111-1119.
3. Backhed F, Manchester JK, Semenkovich CF, Gordon JI. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci USA 2007; 104: 979-984.
4. Ley RE, Backhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JI. Obesity alters gut microbial ecology. Proc Natl Acad Sci USA 2005; 102: 11070-11075.
5. Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007; 56: 1761-1772.
6. Membrez M, Blancher F, Jaquet M, Bibiloni R, Cani PD, Burcelin RG et al. Gut microbiota modulation with norfloxacin and ampicillin enhances glucose tolerance in mice. FASEB J 2008; 22: 2416-2426.
7. Cani PD, Neyrinck AM, Fava F, Knauf C, Burcelin RG, Tuohy KM et al. Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia 2007; 50: 2374-2383.
8. Li Z, Yang S, Lin H, Huang J, Watkins PA, Moser AB et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 2003; 37: 343-350.
9. Naito E, Yoshida Y, Makino K, Kounoshi Y, Kunihiro S, Takahashi R et al. Beneficial effect of oral administration of Lactobacillus casei strain Shirota on insulin resistance in diet-induced obesity mice. J Appl Microbiol 2011; 110: 650-657.
10. Cani PD, Bibiloni R, Knauf C, Waget A, Neyrinck AM, Delzenne NM et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 2008; 57: 1470-1481.
11. Farhadi A, Gundlapalli S, Shaikh M, Frantzides C, Harrell L, Kwasny MM et al. Susceptibility to gut leakiness: a possible mechanism for endotoxaemia in nonalcoholic steatohepatitis. Liver Int 2008; 28: 1026-1033.
12. Lassenius MI, Pietilainen KH, Kaartinen K, Pussinen PJ, Syrjanen J, Forsblom C et al. Bacterial endotoxin activity in human serum is associated with dyslipidemia, insulin resistance, obesity, and chronic inflammation. Diabetes Care 2011; 34: 1809-1815.
13. Wolowczuk I, Verwaerde C, Viltart O, Delanoye A, Delacre M, Pot B et al. Feeding our immune system: impact on metabolism. Clin Dev Immunol 2008; 2008: 639803.
14. Ley RE. Obesity and the human microbiome. Curr Opin Gastroenterol 2010; 26: 5-11.
15. Sheu WH, Chang TM, Lee WJ, Ou HC, Wu CM, Tseng LN et al. Effect of weight loss on proinflammatory state of mononuclear cells in obese women. Obesity Silver Spring) 2008; 16: 1033-1038.
16. Isolauri E, Majamaa H, Arvola T, Rantala I, Virtanen E, Arvilommi H. Lactobacillus casei strain GG reverses increased intestinal permeability induced by cow milk in suckling rats. Gastroenterology 1993; 105: 1643-1650.
17. Zakostelska Z, Kverka M, Klimesova K, Rossmann P, Mrazek J, Kopecny J et al. Lysate of probiotic Lactobacillus casei DN-114 001 ameliorates colitis by strengthening the gut barrier function and changing the gut microenvironment. PLoS One 2011; 6: e27961.
18. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640-1645.
19. Leber B, Stadlbauer V, Stiegler P, Stanzer S, Mayrhauser U, Koestenbauer S et al. Effect of oxidative stress and endotoxin on human serum albumin in brain-dead organ donors. Transl Res 2012; 159: 487-496.
20. Sutherland LR, Verhoef M, Wallace JL, Van Rosendaal G, Crutcher R, Meddings JB. A simple, non-invasive marker of gastric damage: sucrose permeability. Lancet 1994; 343: 998-1000.
21. Pascual S, Such J, Esteban A, Zapater P, Casellas JA, Aparicio JR et al. Intestinal permeability is increased in patients with advanced cirrhosis. Hepatogastroenterology 2003; 50: 1482-1486.
22. Song WB, Lv YH, Zhang ZS, Li YN, Xiao LP, Yu XP et al. Soluble intercellular adhesion molecule-1, D-lactate and diamine oxidase in patients with inflammatory bowel disease. World J Gastroenterol 2009; 15: 3916-3919.
23. Sandek A, Bauditz J, Swidsinski A, Buhner S, Weber-Eibel J, von Haehling S et al. Altered intestinal function in patients with chronic heart failure. J Am Coll Cardiol 2007; 50: 1561-1569.
24. Stadlbauer V, Mookerjee RP, Hodges S, Wright GA, Davies NA, Jalan R. Effect of probiotic treatment on deranged neutrophil function and cytokine responses in patients with compensated alcoholic cirrhosis. J Hepatol 2008; 48: 945-951.
25. Creely SJ, McTernan PG, Kusminski CM, Fisher M, Da Silva NF, Khanolkar M et al. Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. Am J Physiol Endocrinol Metab 2007; 292: E740-E747.
26. Manco M, Putignani L, Bottazzo GF. Gut microbiota, lipopolysaccharides, and innate immunity in the pathogenesis of obesity and cardiovascular risk. Endocr Rev 2010; 31: 817-844.
27. Stadlbauer V, Davies NA, Wright G, Jalan R. Endotoxin measures in patients' sample: how valid are the results? J Hepatol 2007; 47: 726-727author reply 727-3.
28. Sola E, Jover A, Lopez-Ruiz A, Jarabo M, Vaya A, Morillas C et al. Parameters of inflammation in morbid obesity: lack of effect of moderate weight loss. Obes Surg 2009; 19: 571-576.
29. Mazor R, Shurtz-Swirski R, Farah R, Kristal B, Shapiro G, Dorlechter F et al. Primed polymorphonuclear leukocytes constitute a possible link between inflammation and oxidative stress in hyperlipidemic patients. Atherosclerosis 2008; 197: 937-943.
30. Farah R, Shurtz-Swirski R, Dorlechter F. Primed polymorphonuclear leukocytes constitute a possible link between inflammation and oxidative stress in hyperlipidemic patients: effect of statins. Minerva Cardioangiol 2010; 58: 175-181.